We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Protein Technology Helps Heal Intractable Venous Ulcers

By HospiMedica International staff writers
Posted on 24 Aug 2011
A wound-healing invention that is applied using a needle-less syringe quickly adheres to the ulcerous wound bed, offering a revolutionary new treatment. More...


Developed by researchers at the Queensland University of Technology (QUT; Brisbane, Australia), VitroGro improves the delivery of growth stimulating insulin-like growth factors (IGFs) to their receptors on cell surfaces by providing a temporary scaffold on which wound cells can attach and migrate. This is important in chronic wounds, where healing needs to commence from the edges of the wound. Once the wound cells have adhered to a temporary VitroGro matrix, they can repair injured tissue and restore balance by producing a new extracellular matrix (ECM).

In a clinical trial held at the QUT Wound Clinic that evaluated VitroGro in the treatment of venous leg ulcer patients who had not responded to compression therapy--the current standard of care--92 of the patients taking part in the trial were healed partially or completely in 12 weeks. The average reduction in wound size was 65%, with no adverse events reported. The average treatment time that patients' venous ulcers had not responded to expert care before the VitroGro treatment was 37 months.

“We're very excited by these results as it's a new formulation, which is going to be extremely cost effective to the consumer,” said Prof. Zee Upton, PhD, of the QUT Institute of Health and Biomedical Innovation, who is also the technical founder and consulting CSO for Tissue Therapies (Brisbane, Australia), the biotechnology company that is commercially developing VitroGro. “For conditions like venous ulcers where the biology of healing is aberrant, VitroGro provides critical adhesion for cells by forming a scaffold they can attach to and migrate upon. It creates a favorable environment for healing and this is something that has been missing from conventional wound care.”

Venous ulcers tend to occur on the lower leg, just below the ankle to halfway up the calf, and may develop as a result of any injury to the leg or conditions such as varicose vein, blood clot in the leg, multiple pregnancies, overweight, and standing for long periods of time, such as in work related situations. Complications of venous disease often occur due to pooling of fluid in the limb, and may include poor wound healing, edema, restricted mobility due to pain or discomfort when moving, and recurrence of the ulcer.

Related Links:
Queensland University of Technology
Tissue Therapies Limited




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.